{"altmetric_id":4903255,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Sanofi Pasteur MSD"],"first_seen_on":"2015-12-21T03:33:09+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1425844321,"links":["https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01341639?term=v419&rank=3"],"nct_id":"NCT01341639","pubdate":"2011-04-22T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","type":"clinical_trial_study_record"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":4845947,"mean":5.7789424281678,"rank":4055469,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":4845947,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":199534,"mean":9.3279723554501,"rank":156241,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":199534,"percentile":1},"this_journal":{"total_number_of_other_articles":12636,"mean":4.0711205381876,"rank":10853,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":12636,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":514,"mean":4.8401520467836,"rank":420,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":514,"percentile":1}}},"demographics":[],"counts":{"total":{"posts_count":1},"facebook":{"unique_users_count":1,"unique_users":["146559382076530"],"posts_count":1}},"posts":{"facebook":[{"title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12...","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=831340530265075&id=146559382076530","license":"public","citation_ids":[4903255],"posted_on":"2015-03-08T19:52:01+00:00","summary":"This study will determine whether subjects who receive V419 at 2, 3, 4, and 12 months of age have an acceptable immune response to the vaccine. The study will also determine whether the immune response to V419 is similar to that of subjects who receive a l","author":{"name":"The Guggie Daily","url":"https:\/\/www.facebook.com\/146559382076530","facebook_wall_name":"The Guggie Daily","image":"https:\/\/graph.facebook.com\/146559382076530\/picture","id_on_source":"146559382076530"}}]}}